Promising Three-Drug cocktail targets tough leukemia mutation
NCT ID NCT06611839
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 27 times
Summary
This study tests a combination of three drugs—venetoclax, ivosidenib, and azacitidine—in adults with a specific genetic form of acute myeloid leukemia (IDH1-mutated AML). The goal is to see if this triple therapy can improve remission rates and survival compared to standard treatments. The trial enrolls 23 participants and includes induction, consolidation, and maintenance phases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax, ivosidenib, and azacitidine
What this could lead to
If successful, this triple-drug combination could become a new standard treatment for IDH1-mutated AML, offering higher remission rates and longer survival.
What could go wrong
This is an early-phase trial with only 23 participants, so results may not apply to all patients. Side effects from the drugs could be serious, and the regimen may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.